CULVER CITY, Calif., July 28, 2026
Avenda Health announced that its FDA-cleared Unfold AI platform is now being used across the entire prostate cancer care continuum, supporting clinical decision-making for active surveillance, focal therapy, surgery, and radiotherapy. The artificial intelligence-powered platform integrates MRI imaging, pathology, biomarkers, and clinical data to generate personalized three-dimensional (3D) prostate cancer maps, enabling physicians to better visualize tumor location and extent before selecting the most appropriate treatment strategy. The company said the technology is already being adopted by leading academic medical centers and community practices across the United States, reflecting growing demand for AI-driven precision oncology tools that improve treatment planning while preserving patient quality of life.
AI-Powered 3D Cancer Mapping Improves Treatment Planning
Unfold AI combines multiple sources of patient data into an individualized 3D cancer map, allowing clinicians to evaluate disease characteristics with greater precision before intervention. During active surveillance, the platform helps guide repeat biopsies to improve sampling accuracy and confidence in monitoring disease progression. For surgical procedures, including robotic-assisted and nerve-sparing prostatectomy, the AI platform supports surgical planning by identifying tumor boundaries while helping preserve surrounding healthy structures. In focal therapy, such as high-intensity focused ultrasound (HIFU) and cryoablation, Unfold AI determines the optimal treatment zone, and a published Journal of Urology study reported that the technology improved physicians’ ability to predict focal therapy success by 77%. The platform also enables more precise radiotherapy planning by defining targeted radiation margins that reduce unnecessary exposure of healthy tissue.
Clinical Adoption Grows Across Leading U.S. Healthcare Centers
Avenda Health reported that Unfold AI is currently being used at major academic institutions, including the University of California, Los Angeles (UCLA), the University of Alabama at Birmingham, and the University of Michigan Health, as well as multiple community-based urology practices across Arizona, Maryland, Florida, New York, and California. Rather than directing physicians toward a single treatment approach, the platform provides comprehensive disease mapping that supports informed decision-making across multiple therapeutic options. According to the company, the technology has demonstrated the ability to shift physician treatment recommendations toward less invasive interventions in approximately one-third of cases, allowing more personalized care based on each patient’s unique disease profile.
Advertisement
Approval Strengthens Precision Oncology and PSMA-Targeted Treatment
As healthcare systems increasingly adopt artificial intelligence to improve clinical decision-making, Unfold AI represents a significant advancement in personalized prostate cancer care by combining imaging, pathology, biomarker, and clinical information into a unified treatment planning platform. The company believes improved cancer localization enables physicians to select more effective therapies while reducing unnecessary procedures and healthcare costs. By supporting treatment decisions across active surveillance, surgery, focal therapy, and radiation oncology, the FDA-cleared platform is positioned to help establish a new standard for AI-guided precision medicine in prostate cancer, with the potential to improve clinical outcomes and preserve patient quality of life through more individualized treatment strategies.
Source: Avenda Health press release
